Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?

Jefferies on Pharmaceuticals: Global Pharmaceuticals Q2'12 Earnings Preview; Where is it Safe to Hide?

Analyst, Jeffrey Holford, said, "We expect a tough earnings season as patent expiries, European pricing and FX headwinds for most companies drag on revenues and earnings. The recent macro rotation towards the sector could exacerbate the market reaction to any earnings misses in our view. We see Novo Nordisk (NYSE: NVO) and Abbott (NYSE: ABT) as the best plays on Q2'12 earnings, with AstraZeneca (NYSE: AZN), GlaxoSmithKline (NYSE: GSK), Bristol-Myers (NYSE: BMY), Novartis (NYSE: NVS) and Pfizer (NYSE: PFE) as most likely to disappoint."

Nomura maintains a 'Buy' on Abbott (NYSE: ABT), lowers PT from $76 to $75.

Maintains a 'Buy' on Bristol-Myers (NYSE: BMY), PT raised $1 to $39.

Maintains a 'Buy' on J&J (NYSE: JNJ), raises PT from $72 to $75.

Keeps 'Hold' on Eli Lilly (NYSE: LLY), PT raised $1 to $37.

Maintains a 'Hold' on Merck (NYSE: MRK), PT raised $2 to $42.

Maintains a 'Buy' on Pfizer (NYSE: PFE), PT lowered $1 to $25.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• CACI International (CACI) PT Raised to $440 at Stifel
• RBB Bancorp (RBB) PT Raised to $22 at Keefe, Bruyette & Woods
• Opthea Ltd. (OPT) PT Raised to $18 at Oppenheimer